Genomic Health's liquid biopsy mutation panel rates high in sensitivity, reproducibility

Genomic Health has completed testing of its Oncotype SEQ Liquid Select, showing the liquid biopsy mutation panel to be sensitive, specific and reproducible.

The system uses sequencing from a blood sample to analyze cell-free DNA of a tumor and examines the four main genomic alterations that cause the development of malignant and therapy-resistant tumors. By only reporting the clinically actionable results, the test provides specific information to the patient to manage stage IV tumors. The test can then match the patient with potential clinical trials most likely to treat their specific type of tumor.

Test conducted on the sensitivity, specificity and reproducibility of the Oncotype SEQ showed that all measurements were positive for providing the best results to patients. The per sample specificity was measured at 99 percent, sensitivity at 95 percent and reproducible at 95 percent.

"The high specificity, sensitivity and reproducibility of Oncotype SEQ validated in this study ensures reliable and actionable liquid biopsy test results that physicians can routinely use in clinical practice to help drive precision medicine and enable patients to make more informed treatment decisions," said Phil Febbo, MD, Genomic Health's chief medical officer. "Delivered through our Oncotype IQ Genomic Intelligence Platform, the test is designed to address the needs of about 450,000 patients who recur or present with late-stage disease each year in the United States alone."